Phase 2 Dose Optimization Trial of Everolimus Post-Bland Hepatic Artery Embolization (Evero-Embo) in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis
Lowell Anthony, MD
Summary
This study is being done to learn whether people with neuroendocrine tumors (NETs) that have spread to the liver can safely tolerate a lower dose of everolimus after bland hepatic artery embolization (HAE).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients must have histologically or cytologically confirmed Grade 1 or 2 NET with measurable liver metastasis (≥1.0 cm). * Morphologically progressive disease by RECIST 1.1 and/or ≥25% but ≤75% tumor burden in the liver. * Prior tolerance of at least 5 mg daily everolimus for ≥5 days pre-HAE. NOTE: There is no maximum amount of time a patient may be taking Everolimus before HAE as the study focuses on after the pre-HAE dose is established. * Prior therapy: Patients are eligible regardless of the number or type of prior therapies and without a requirement to have receive…
Interventions
- DrugEverolimus
Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization
- ProcedureBland Hepatic Artery Embolization
Bland Hepatic Artery Embolization (HAE) will occur on Day 0.
Location
- University of KentuckyLexington, Kentucky